机构:[1]Department of Cell Biology and Genetics, Shenzhen University Health Science Center, Shenzhen 518060, GuangdongProvince, China深圳市康宁医院深圳医学信息中心[2]Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People’s Hospital of Shenzhen,Shenzhen 518035, Guangdong Province, China深圳市第二人民医院深圳市康宁医院深圳医学信息中心[3]Department of Pathology, The First Affiliated Hospital of Shenzhen University, Second People’s Hospital of Shenzhen,Shenzhen 518035, Guangdong Province, China深圳市第二人民医院深圳市康宁医院深圳医学信息中心[4]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University,Guangzhou 510632, Guangdong Province, China[5]Department of Pathology, Shenzhen Nanshan People’s Hospital, Shenzhen 518052, Guangdong Province, China深圳市康宁医院深圳市南山区人民医院深圳医学信息中心
Cyclin-dependent kinase 3 (CDK3), a member of CDK family, is involved in G0/G1 and G1/S cell cycle transitions. Although several researchers discovered that CDK3 related to cell growth in some kinds of cancer, the functions of CDK3 during tumor development remains unclear. Here, we first found that the expression of CDK3 was higher in primary tumors of non-metastatic breast cancer compared with those in metastatic breast cancer. Overexpression of CDK3 suppressed cell migration and invasion of breast cancer cells, and decreased the metastasis in nude mice. We further identified miR-4469 was a negative regulator of CDK3 by directly targeting its 3'-untranslated region (UTR). The increase of motility induced by miR-4469 could be abolished by CDK3 overexpression. Moreover, RNA-seq analysis revealed that Wnt pathway may be inhibited by CDK3 expression, which was subsequently confirmed by western blot. Moreover, Wnt3a treatment abolished the inhibitory role of CDK3 in cell motility, suggesting that Wnt signaling is the potential downstream of CDK3. In conclusion, these results support that CDK3 which is targeted by miR-4469 suppresses breast cancer metastasis by inhibiting Wnt/β-catenin pathway.
基金:
grants from the National Natural Science Foundation of China (81372149, 81401894, 81402289), the National Science Foundation Projects of Guangdong Province (2014A030313547), Shenzhen Municipal Government of China (JCYJ20160427105140594, KQCX20140519104925300, JCYJ20140418091413510, JCYJ20160307155641741, JCYJ20160422091914681, GJHZ20160301164637011).
第一作者机构:[1]Department of Cell Biology and Genetics, Shenzhen University Health Science Center, Shenzhen 518060, GuangdongProvince, China[4]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University,Guangzhou 510632, Guangdong Province, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Ting Cao,Tian Xiao,Guanqun Huang,et al.CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway.[J].ONCOTARGET.2017,8(49):84917-84927.doi:10.18632/oncotarget.18171.
APA:
Ting Cao,Tian Xiao,Guanqun Huang,Yafei Xu,Joe Jiang Zhu...&Duo Zheng.(2017).CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway..ONCOTARGET,8,(49)
MLA:
Ting Cao,et al."CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway.".ONCOTARGET 8..49(2017):84917-84927